284 related articles for article (PubMed ID: 22723949)
1. TYK2 kinase activity is required for functional type I interferon responses in vivo.
Prchal-Murphy M; Semper C; Lassnig C; Wallner B; Gausterer C; Teppner-Klymiuk I; Kobolak J; Müller S; Kolbe T; Karaghiosoff M; Dinnyés A; Rülicke T; Leitner NR; Strobl B; Müller M
PLoS One; 2012; 7(6):e39141. PubMed ID: 22723949
[TBL] [Abstract][Full Text] [Related]
2. The Atlantic salmon protein tyrosine kinase Tyk2: molecular cloning, modulation of expression and function.
Sobhkhez M; Hansen T; Iliev DB; Skjesol A; Jørgensen JB
Dev Comp Immunol; 2013 Dec; 41(4):553-63. PubMed ID: 23872231
[TBL] [Abstract][Full Text] [Related]
3. JAK/STAT/SOCS-signaling pathway and colon and rectal cancer.
Slattery ML; Lundgreen A; Kadlubar SA; Bondurant KL; Wolff RK
Mol Carcinog; 2013 Feb; 52(2):155-66. PubMed ID: 22121102
[TBL] [Abstract][Full Text] [Related]
4. Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2).
Min X; Ungureanu D; Maxwell S; Hammarén H; Thibault S; Hillert EK; Ayres M; Greenfield B; Eksterowicz J; Gabel C; Walker N; Silvennoinen O; Wang Z
J Biol Chem; 2015 Nov; 290(45):27261-27270. PubMed ID: 26359499
[TBL] [Abstract][Full Text] [Related]
5. Luteolin sensitizes the antiproliferative effect of interferon α/β by activation of Janus kinase/signal transducer and activator of transcription pathway signaling through protein kinase A-mediated inhibition of protein tyrosine phosphatase SHP-2 in cancer cells.
Tai Z; Lin Y; He Y; Huang J; Guo J; Yang L; Zhang G; Wang F
Cell Signal; 2014 Mar; 26(3):619-28. PubMed ID: 24333668
[TBL] [Abstract][Full Text] [Related]
6. Suppressor of cytokine signaling (SOCS) 1 inhibits type I interferon (IFN) signaling via the interferon alpha receptor (IFNAR1)-associated tyrosine kinase Tyk2.
Piganis RA; De Weerd NA; Gould JA; Schindler CW; Mansell A; Nicholson SE; Hertzog PJ
J Biol Chem; 2011 Sep; 286(39):33811-8. PubMed ID: 21757742
[TBL] [Abstract][Full Text] [Related]
7. Two rare disease-associated Tyk2 variants are catalytically impaired but signaling competent.
Li Z; Gakovic M; Ragimbeau J; Eloranta ML; Rönnblom L; Michel F; Pellegrini S
J Immunol; 2013 Mar; 190(5):2335-44. PubMed ID: 23359498
[TBL] [Abstract][Full Text] [Related]
8. Tyk2 tyrosine kinase expression is required for the maintenance of mitochondrial respiration in primary pro-B lymphocytes.
Potla R; Koeck T; Wegrzyn J; Cherukuri S; Shimoda K; Baker DP; Wolfman J; Planchon SM; Esposito C; Hoit B; Dulak J; Wolfman A; Stuehr D; Larner AC
Mol Cell Biol; 2006 Nov; 26(22):8562-71. PubMed ID: 16982690
[TBL] [Abstract][Full Text] [Related]
9. Novel functions of tyrosine kinase 2 in the antiviral defense against murine cytomegalovirus.
Strobl B; Bubic I; Bruns U; Steinborn R; Lajko R; Kolbe T; Karaghiosoff M; Kalinke U; Jonjic S; Müller M
J Immunol; 2005 Sep; 175(6):4000-8. PubMed ID: 16148148
[TBL] [Abstract][Full Text] [Related]
10. Tyrosine kinase 2 (TYK2) in cytokine signalling and host immunity.
Strobl B; Stoiber D; Sexl V; Mueller M
Front Biosci (Landmark Ed); 2011 Jun; 16(9):3214-32. PubMed ID: 21622231
[TBL] [Abstract][Full Text] [Related]
11. Myxoma virus selectively disrupts type I interferon signaling in primary human fibroblasts by blocking the activation of the Janus kinase Tyk2.
Wang F; Barrett JW; Shao Q; Gao X; Dekaban GA; McFadden G
Virology; 2009 Apr; 387(1):136-46. PubMed ID: 19254804
[TBL] [Abstract][Full Text] [Related]
12. Synthetic Heterodimers of Type III Interferon Receptors Require TYK2 for STAT Activation.
Mesev EV; Guare EG; Ploss A; Toettcher JE
J Interferon Cytokine Res; 2023 Sep; 43(9):414-426. PubMed ID: 37725008
[TBL] [Abstract][Full Text] [Related]
13. Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 Pathway.
Loo WJ; Turchin I; Prajapati VH; Gooderham MJ; Grewal P; Hong CH; Sauder M; Vender RB; Maari C; Papp KA
J Cutan Med Surg; 2023; 27(1_suppl):3S-24S. PubMed ID: 36519621
[TBL] [Abstract][Full Text] [Related]
14. Requirement of catalytically active Tyk2 and accessory signals for the induction of TRAIL mRNA by IFN-beta.
Rani MR; Pandalai S; Shrock J; Almasan A; Ransohoff RM
J Interferon Cytokine Res; 2007 Sep; 27(9):767-79. PubMed ID: 17892398
[TBL] [Abstract][Full Text] [Related]
15. Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis.
Roskoski R
Pharmacol Res; 2023 Mar; 189():106642. PubMed ID: 36754102
[TBL] [Abstract][Full Text] [Related]
16. Distinct domains of the protein tyrosine kinase tyk2 required for binding of interferon-alpha/beta and for signal transduction.
Velazquez L; Mogensen KE; Barbieri G; Fellous M; Uzé G; Pellegrini S
J Biol Chem; 1995 Feb; 270(7):3327-34. PubMed ID: 7531704
[TBL] [Abstract][Full Text] [Related]
17. Transcriptome analysis reveals a major impact of JAK protein tyrosine kinase 2 (Tyk2) on the expression of interferon-responsive and metabolic genes.
Vogl C; Flatt T; Fuhrmann B; Hofmann E; Wallner B; Stiefvater R; Kovarik P; Strobl B; Müller M
BMC Genomics; 2010 Mar; 11():199. PubMed ID: 20338026
[TBL] [Abstract][Full Text] [Related]
18. Beta interferon and oncostatin M activate Raf-1 and mitogen-activated protein kinase through a JAK1-dependent pathway.
Stancato LF; Sakatsume M; David M; Dent P; Dong F; Petricoin EF; Krolewski JJ; Silvennoinen O; Saharinen P; Pierce J; Marshall CJ; Sturgill T; Finbloom DS; Larner AC
Mol Cell Biol; 1997 Jul; 17(7):3833-40. PubMed ID: 9199317
[TBL] [Abstract][Full Text] [Related]
19. Activation of the protein tyrosine kinase tyk2 by interferon alpha/beta.
Barbieri G; Velazquez L; Scrobogna M; Fellous M; Pellegrini S
Eur J Biochem; 1994 Jul; 223(2):427-35. PubMed ID: 8055912
[TBL] [Abstract][Full Text] [Related]
20. A novel highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2) can block inflammation- and autoimmune-related pathways.
Chen CX; Zhang W; Qu S; Xia F; Zhu Y; Chen B
Cell Commun Signal; 2023 Oct; 21(1):287. PubMed ID: 37845748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
